Vertex Pharmaceuticals (VRTX) Receivables (2009 - 2026)

Vertex Pharmaceuticals has reported Receivables for 18 years, with the latest figure at $2.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 10.58% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $2.0 billion (up 10.58% YoY), and the FY2025 full-year result was $2.1 billion, up 27.55% from the prior year.
• Receivables for Q1 2026 stood at $2.0 billion, down from $2.1 billion in the prior quarter.
• The five-year high for Receivables was $2.1 billion in Q4 2025, with the low at $1.3 billion in Q1 2022.
• Average Receivables over 5 years is $1.7 billion, with a median of $1.6 billion recorded in 2024.
• Year-over-year, Receivables soared 43.45% in 2022 and grew 0.66% in 2025.
• Tracing VRTX's Receivables over 5 years: stood at $1.4 billion in 2022, then advanced by 8.4% to $1.6 billion in 2023, then gained by 2.94% to $1.6 billion in 2024, then rose by 27.55% to $2.1 billion in 2025, then retreated by 2.76% to $2.0 billion in 2026.
• The last three Receivables figures came in at $2.0 billion (Q1 2026), $2.1 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.

Peer Comparison